- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | BioAdaptives, Inc.: BioAdaptives to Acquire Xycota Biosciences to Pursue the Potential of At Home Psilocybin Treatment | 318 | ACCESS Newswire | Xycota's lead program aims to deliver clinical benefit from low-dose psilocybin without hallucinogenic effects, with mild PTSD as its initial target. LAS VEGAS, NV AND SHERIDAN, WY / ACCESS Newswire... ► Artikel lesen | |
| 04.11. | BIOADAPTIVES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 23.09. | BioAdaptives, Inc.: BioAdaptives Highlights Michael Bisping's MyndMed Routine in UFC 331 Pre-Show Instagram Video | 475 | ACCESS Newswire | UFC Hall of Famer and MyndSystem brand ambassador shares how the daytime formula fits into his preparation for live broadcasts, commentary, and podcasting. LAS VEGAS, NV / ACCESS Newswire / September... ► Artikel lesen | |
| 03.09. | BioAdaptives, Inc.: BioAdaptives Confirms First Commercial Orders of XcellaraHeart and Outlines Capital Restructuring Progress | 581 | ACCESS Newswire | Initial XcellaraHeart orders ship next week, marking the commercial launch of the Xcellara cellular wellness platform; Company prepares XcellaraResilience for October launch and highlights the retirement... ► Artikel lesen | |
| 31.08. | BioAdaptives, Inc.: UFC Hall of Famer Michael Bisping Joins BioAdaptives to Champion MyndSystem | 387 | ACCESS Newswire | Former UFC middleweight champion and current broadcaster will help promote MyndSystem as part of a disciplined day-and-night performance routine LAS VEGAS, NV / ACCESS Newswire / August 31, 2026 / BioAdaptives... ► Artikel lesen | |
| 19.08. | BIOADAPTIVES, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.08. | BIOADAPTIVES, INC. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| BIOADAPTIVES Aktie jetzt für 0€ handeln | |||||
| 13.08. | BioAdaptives, Inc. Announces CEO's Share Cancellation and Provides Capital Restructure Update | 425 | ACCESS Newswire | Company outlines adjustments to public float, lender lock-up and leak-out agreements, and growth-funding structure. LAS VEGAS, NV / ACCESS Newswire / August 13, 2026 / BioAdaptives, Inc. (OTCID:BDPT)... ► Artikel lesen | |
| 12.08. | BioAdaptives, Inc.: BioAdaptives Inc. Introduces XcellaraHeart: the World's First Stem Cell Mobilizer with a Targeted Cardiac Homing Signal | 353 | ACCESS Newswire | The flagship product of the new Xcellara cellular wellness platform is backed by a randomized, double-blind, placebo-controlled human clinical trial that showed an average increase of 268.8% in circulating... ► Artikel lesen | |
| 04.08. | BioAdaptiveas, Inc.: BioAdaptives Explains the Scientific Basis of the Dual-Action Xcellara "Supply and Direction" Platform | 310 | ACCESS Newswire | The Platform integrates clinically researched stem and progenitor cell mobilization with ingredients that have been studied for their roles in tissue signaling pathways. LAS VEGAS, NV / ACCESS Newswire... ► Artikel lesen | |
| 03.08. | BioAdaptives, Inc.: BioAdaptives Inc. Opens Commercial Ordering Window for XcellaraHeart Cellular Wellness Formula | 309 | ACCESS Newswire | Retirement of Largest Outstanding Convertible Debt Clears Runway for High-Growth E-Commerce Rollout of a Targeted Stem Cell Platform LAS VEGAS, NV / ACCESS Newswire / August 3, 2026 / BioAdaptives,... ► Artikel lesen | |
| 30.07. | BioAdaptives, Inc.: BioAdaptives Inc. Eliminates Major Market Overhang by Retiring the Debt of the Largest Convertible Commercial Investor | 718 | ACCESS Newswire | Strategic transaction alleviates dilutive pressure, showcasing financial strength and aligning shareholder value prior to product launches. LAS VEGAS, NV / ACCESS Newswire / July 30, 2026 / BioAdaptives... ► Artikel lesen | |
| 29.07. | BioAdaptives, Inc.: BioAdaptives Inc. Reports Scaling of E-Commerce Footprint and Consumer Reach for MyndSystem Nootropic Platform | 938 | ACCESS Newswire | LAS VEGAS, NV / ACCESS Newswire / July 29, 2026 / BioAdaptives, Inc. (OTCID:BDPT), a developer of natural, science-backed wellness solutions, today announced a significant expansion of its digital storefront... ► Artikel lesen | |
| 23.07. | BioAdaptives Inc. Announces Operational Readiness and Completion of the Commercial Supply Chain for Upcoming Product Launches | 257 | GlobeNewswire (Europe) | LAS VEGAS, July 23, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT), a developer of science-driven wellness products, today announces the successful completion of its commercial... ► Artikel lesen | |
| 16.07. | BioAdaptives Inc.: BioAdaptives Outlines Xcellara Platform Strategy: Integrating Stem Cell Supply and Direction for Targeted Wellness | 264 | GlobeNewswire (Europe) | LAS VEGAS, July 16, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives® Inc. (OTC: BDPT) today outlined the scientific strategy behind its Xcellara cellular wellness platform ahead of the August 1,... ► Artikel lesen | |
| 15.07. | BioAdaptives Inc.: BioAdaptives Inc. Announces XcellaraHeart, a Cardiovascular Wellness Formula Built on Xcellara's Human-Clinical Data Demonstrating a 268.8% Increase in Circulating Stem/Progenitor-Type Cells | 215 | GlobeNewswire (Europe) | LAS VEGAS, July 15, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives® Inc. (OTC: BDPT), developer of the Xcellara line of stem cell mobilization supplements, today announced the upcoming commercial... ► Artikel lesen | |
| 25.06. | BioAdaptives Inc.: BioAdaptives Completes MyndSystem Platform with TruShield Certification of MyndRenew, Securing Full WADA Compliance for Professional Athletes and Expanding Market Opportunity | 450 | GlobeNewswire (Europe) | LAS VEGAS, June 25, 2026 (GLOBE NEWSWIRE) -- via IBN - BioAdaptives, Inc. (OTC: BDPT), the parent company of MyndSystem, today announced that its nighttime repair formula, MyndRenew, has received... ► Artikel lesen | |
| 20.05. | BioAdaptives Inc.: BioAdaptives Launches MyndSystem Website - The First Supplement Platform Designed to Support Both Daytime Cognitive Performance and Overnight Brain Recovery | 1 | GlobeNewswire (USA) | ||
| 06.05. | BioAdaptives Inc.: BioAdaptives, Inc. Launches MyndRenew to Complete the 24-Hour Brain Performance Cycle | 261 | GlobeNewswire (Europe) | LAS VEGAS, May 06, 2026 (GLOBE NEWSWIRE) -- via IBN - More than 1 in 3 American adults report insufficient sleep - a deficit that research increasingly links to measurable declines in next-day cognitive... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PEPGEN | 4,620 | +0,22 % | PepGen soars on promising early data for muscular dystrophy drug | ||
| PRAXIS PRECISION MEDICINES | 337,27 | -0,09 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| DISC MEDICINE | 84,77 | +0,15 % | Disc Medicine auf der Guggenheim-Konferenz: Finanzstarker Vorstoß in die Vermarktungsphase | ||
| ARCUTIS BIOTHERAPEUTICS | 27,385 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DYNE THERAPEUTICS | 17,920 | 0,00 % | Dyne Therapeutics, Inc. - 8-K, Current Report | ||
| ERASCA | 15,480 | 0,00 % | Tango Therapeutics, Inc.; Erasca, Inc.: Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 | ||
| EDGEWISE THERAPEUTICS | 46,570 | +0,09 % | Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring | - Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability -- STRATUS-HCM includes two independent... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,600 | -0,13 % | Cogent Biosciences auf Guggenheim-Konferenz: Marktstart rückt näher | ||
| TANGO THERAPEUTICS | 24,280 | -0,08 % | Jefferies raises Tango Therapeutics stock price target on trial data | ||
| ABSCI | 9,970 | 0,00 % | Absci auf der Guggenheim-Gesundheitskonferenz: Eigene Pipeline rückt in den Fokus | ||
| KYMERA THERAPEUTICS | 136,60 | -0,03 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,160 | +0,04 % | Jones Trading initiates Beam Therapeutics stock coverage with buy rating | ||
| ENLIVEN THERAPEUTICS | 51,29 | +0,18 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update | Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial On track to initiate ENABLE-2 before year-end 2026 Strong balance sheet with $884 million in cash, cash equivalents... ► Artikel lesen | |
| JANUX THERAPEUTICS | 12,040 | 0,00 % | Janux reports phase 1 data for autoimmune drug candidate JANX011 | ||
| RECURSION PHARMACEUTICALS | 3,550 | 0,00 % | Recursion Pharmaceuticals (NDQ:RXRX): Why Is Nvidia An Investor? Because Its AI Platform Could Change Drug Discovery, Or Could It? |
Das Unternehmen BIOADAPTIVES INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOADAPTIVES INC finden Sie auf Wallstreet Online.